Role of genetic polymorphisms and ovarian cancer susceptibility

Molecular Oncology

Volumn 3, Issue 2, 2009, Pages 171-181

  Fasching, Peter A ^a   Gayther, Simon ^b   Pearce, Leigh ^c   Schildkraut, Joellen M ^d   Goode, Ellen ^e   Thiel, Falk ^f   Chenevix Trench, Georgia ^g   Chang Claude, Jenny ^h   Wang Gohrke, Shan ⁱ   Ramus, Susan ^e   Pharoah, Paul ^j   Berchuck, Andrew ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

ⁱ UNIVERSITY HOSPITAL ULM   (Germany)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

Early detection; Genetic; Ovarian cancer; Polymorphism; Risk; SNP

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER MORTALITY; CANCER RISK; CANCER SUSCEPTIBILITY; EARLY DIAGNOSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; ONCOGENE; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; REVIEW; SALPINGOOOPHORECTOMY; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE TUBE CARCINOMA;

CASE-CONTROL STUDIES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTICENTER STUDIES AS TOPIC; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 63549147327     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2009.01.008     Document Type: Review

References (63)

1. Agorastos T., Masouridou S., Lambropoulos A.F., Chrisafi S., Miliaras D., Pantazis K., Constantinides T.C., Kotsis A., and Bontis I. P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur. J. Cancer Prev. 13 (2004) 277-280
2. Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., Loman N., Olsson H., Johannsson O., Borg A., Pasini B., Radice P., Manoukian S., Eccles D.M., Tang N., Olah E., Anton-Culver H., Warner E., Lubinski J., Gronwald J., Gorski B., Tulinius H., Thorlacius S., Eerola H., Nevanlinna H., Syrjakoski K., Kallioniemi O.P., Thompson D., Evans C., Peto J., Lalloo F., Evans D.G., and Easton D.F. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72 (2003) 1117-1130
3. Auranen A., Song H., Waterfall C., Dicioccio R.A., Kuschel B., Kjaer S.K., Hogdall E., Hogdall C., Stratton J., Whittemore A.S., Easton D.F., Ponder B.A., Novik K.L., Dunning A.M., Gayther S., and Pharoah P.D. Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int. J. Cancer 117 (2005) 611-618
4. Beesley J., Jordan S.J., Spurdle A.B., Song H., Ramus S.J., Kjaer S.K., Hogdall E., DiCioccio R.A., McGuire V., Whittemore A.S., Gayther S.A., Pharoah P.D., Webb P.M., and Chenevix-Trench G. Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 2557-2565
5. Berchuck A., Schildkraut J.M., Marks J.R., and Futreal P.A. Managing hereditary ovarian cancer risk. Cancer 86 (1999) 2517-2524
6. Bernard-Gallon D., Bosviel R., Delort L., Fontana L., Chamoux A., Rabiau N., Kwiatkowski F., Chalabi N., Satih S., and Bignon Y.J. DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk. Mol. Cancer 7 (2008) 36
7. Campbell I.G., Eccles D.M., and Choong D.Y. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett. 240 (2006) 195-197
8. Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., and Lander E.S. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat. Genet. 22 (1999) 231-238
9. Carlson C.S., Eberle M.A., Kruglyak L., and Nickerson D.A. Mapping complex disease loci in whole-genome association studies. Nature 429 (2004) 446-452
10. Couch F.J., and Weber B.L. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum. Mutat. 8 (1996) 8-18
11. Dalan A.B., Ergen A., Yilmaz H., Karateke A., and Isbir T. Manganese superoxide dismutase gene polymorphism, MnSOD plasma levels and risk of epithelial ovarian cancer. J. Obstet. Gynaecol. Res. 34 (2008) 878-884
12. De Vivo I., Hankinson S.E., Colditz G.A., and Hunter D.J. A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res. 63 (2003) 5236-5238
13. De Vivo I., Huggins G.S., Hankinson S.E., Lescault P.J., Boezen M., Colditz G.A., and Hunter D.J. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 12263-12268
14. Dunning A.M., Dowsett M., Healey C.S., Tee L., Luben R.N., Folkerd E., Novik K.L., Kelemen L., Ogata S., Pharoah P.D., Easton D.F., Day N.E., and Ponder B.A. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J. Natl. Cancer Inst. 96 (2004) 936-945
15. Fairfield K.M., Hunter D.J., Fuchs C.S., Colditz G.A., and Hankinson S.E. Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 13 (2002) 535-542
16. Fasching P.A., Loehberg C.R., Strissel P.L., Lux M.P., Bani M.R., Schrauder M., Geiler S., Ringleff K., Oeser S., Weihbrecht S., Schulz-Wendtland R., Hartmann A., Beckmann M.W., and Strick R. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Res. Treat. 112 (2008) 89-98
17. Frank T.S., Manley S.A., Olopade O.I., Cummings S., Garber J.E., Bernhardt B., Antman K., Russo D., Wood M.E., Mullineau L., Isaacs C., Peshkin B., Buys S., Venne V., Rowley P.T., Loader S., Offit K., Robson M., Hampel H., Brener D., Winer E.P., Clark S., Weber B., Strong L.C., Thomas A., et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J. Clin. Oncol. 16 (1998) 2417-2425
18. Gayther S.A., Song H., Ramus S.J., Kjaer S.K., Whittemore A.S., Quaye L., Tyrer J., Shadforth D., Hogdall E., Hogdall C., Blaeker J., DiCioccio R., McGuire V., Webb P.M., Beesley J., Green A.C., Whiteman D.C., Goodman M.T., Lurie G., Carney M.E., Modugno F., Ness R.B., Edwards R.P., Moysich K.B., Goode E.L., Couch F.J., Cunningham J.M., Sellers T.A., Wu A.H., Pike M.C., Iversen E.S., Marks J.R., Garcia-Closas M., Brinton L., Lissowska J., Peplonska B., Easton D.F., Jacobs I., Ponder B.A., Schildkraut J., Pearce C.L., Chenevix-Trench G., Berchuck A., and Pharoah P.D. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 67 (2007) 3027-3035
19. Giangrande P.H., Kimbrel E.A., Edwards D.P., and McDonnell D.P. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol. Cell. Biol. 20 (2000) 3102-3115
20. Goodman M.T., Ferrell R., McDuffie K., Thompson P.J., Wilkens L.R., Bushley A.W., Tung K.H., Carney M.E., and Ness R.B. Calcitonin gene polymorphism CALCA-624 (T/C) and ovarian cancer. Environ. Mol. Mutagen. 46 (2005) 53-58
21. Goodman M.T., Lurie G., Thompson P.J., McDuffie K.E., and Carney M.E. Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk. Endocr. Relat. Cancer 15 (2008) 1055-1060
22. Grimm C., Polterauer S., Zeillinger R., Tempfer C., Sliutz G., Reinthaller A., and Hefler L.A. The prohibitin 3′ untranslated region polymorphism in patients with ovarian cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 137 (2008) 236-239
23. Haiman C.A., Dossus L., Setiawan V.W., Stram D.O., Dunning A.M., Thomas G., Thun M.J., Albanes D., Altshuler D., Ardanaz E., Boeing H., Buring J., Burtt N., Calle E.E., Chanock S., Clavel-Chapelon F., Colditz G.A., Cox D.G., Feigelson H.S., Hankinson S.E., Hayes R.B., Henderson B.E., Hirschhorn J.N., Hoover R., Hunter D.J., Kaaks R., Kolonel L.N., Le Marchand L., Lenner P., Lund E., Panico S., Peeters P.H., Pike M.C., Riboli E., Tjonneland A., Travis R., Trichopoulos D., Wacholder S., and Ziegler R.G. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res. 67 (2007) 1893-1897
24. Jakubowska A., Gronwald J., Menkiszak J., Gorski B., Huzarski T., Byrski T., Edler L., Lubinski J., Scott R.J., and Hamann U. Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk. J. Med. Genet. 44 (2007) 408-411
25. Ju W., Kim J.W., Park N.H., Song Y.S., Kim S.C., Kang S.B., and Lee H.P. Matrix metalloproteinase-1 promoter polymorphism and epithelial ovarian cancer: does ethnicity matter?. J. Obstet. Gynaecol. Res. 33 (2007) 155-160
26. Kelemen L., Spurdle A.B., Purdie D.M., Gertig D., and Chenevix-Trench G. RAD52 Y415X truncation polymorphism and epithelial ovarian cancer risk in Australian women. Cancer Lett. 218 (2005) 191-197
27. Kelemen L.E., Sellers T.A., Schildkraut J.M., Cunningham J.M., Vierkant R.A., Pankratz V.S., Fredericksen Z.S., Gadre M.K., Rider D.N., Liebow M., and Goode E.L. Genetic variation in the one-carbon transfer pathway and ovarian cancer risk. Cancer Res. 68 (2008) 2498-2506
28. Lefkowitz E.S., and Garland C.F. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int. J. Epidemiol. 23 (1994) 1133-1136
29. Leite D.B., Junqueira M.G., de Carvalho C.V., Massad-Costa A.M., Goncalves W.J., Nicolau S.M., Lopes L.A., Baracat E.C., and da Silva I.D. Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer. Steroids 73 (2008) 676-680
30. Li Y., Jin X., Kang S., Wang Y., Du H., Zhang J., Guo W., Wang N., and Fang S. Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Gynecol. Oncol. 101 (2006) 92-96
31. Li Y., Liang J., Kang S., Dong Z., Wang N., Xing H., Zhou R., Li X., and Zhao X. E-cadherin gene polymorphisms and haplotype associated with the occurrence of epithelial ovarian cancer in Chinese. Gynecol. Oncol. 108 (2008) 409-414
32. Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J., Koskenvuo M., Pukkala E., Skytthe A., and Hemminki K. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343 (2000) 78-85
33. Long J.R., Kataoka N., Shu X.O., Wen W., Gao Y.T., Cai Q., and Zheng W. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 2115-2122
34. Merritt M.A., Green A.C., Nagle C.M., and Webb P.M. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int. J. Cancer 122 (2008) 170-176
35. Nam E.J., and Kim Y.T. Alteration of cell-cycle regulation in epithelial ovarian cancer. Int. J. Gynecol. Cancer (2008)
36. National Institutes of Health. Policy for sharing of data obtained in NIH supported or conducted genome-wide association studies (GWAS). Fed. Regist. 72 (2007) 49290-49297
37. Ness R.B. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am. J. Obstet. Gynecol. 189 (2003) 280-294
38. Pearce C.L., Wu A.H., Gayther S.A., Bale A.E., Beck P.A., Beesley J., Chanock S., Cramer D.W., DiCioccio R., Edwards R., Fredericksen Z.S., Garcia-Closas M., Goode E.L., Green A.C., Hartmann L.C., Hogdall E., Kjaer S.K., Lissowska J., McGuire V., Modugno F., Moysich K., Ness R.B., Ramus S.J., Risch H.A., Sellers T.A., Song H., Stram D.O., Terry K.L., Webb P.M., Whiteman D.C., Whittemore A.S., Zheng W., Pharoah P.D., Chenevix-Trench G., Pike M.C., Schildkraut J., and Berchuck A. Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br. J. Cancer 98 (2008) 282-288
39. Pike M.C., Pearce C.L., Peters R., Cozen W., Wan P., and Wu A.H. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil. Steril. 82 (2004) 186-195
40. Pharoah P.D., Antoniou A.C., Easton D.F., and Ponder B.A. Polygenes, risk prediction, and targeted prevention of breast cancer. N. Engl. J. Med 358 (2008) 2796-2803
41. Ramus S.J., Vierkant R.A., Johnatty S.E., Pike M.C., Van Den Berg D.J., Wu A.H., Pearce C.L., Menon U., Gentry-Maharaj A., Gayther S.A., Dicioccio R.A., McGuire V., Whittemore A.S., Song H., Easton D.F., Pharoah P.D., Garcia-Closas M., Chanock S., Lissowska J., Brinton L., Terry K.L., Cramer D.W., Tworoger S.S., Hankinson S.E., Berchuck A., Moorman P.G., Schildkraut J.M., Cunningham J.M., Liebow M., Kjaer S.K., Hogdall E., Hogdall C., Blaakaer J., Ness R.B., Moysich K.B., Edwards R.P., Carney M.E., Lurie G., Goodman M.T., Wang-Gohrke S., Kropp S., Chang-Claude J., Webb P.M., Chen X., Beesley J., Chenevix-Trench G., and Goode E.L. Consortium analysis of 7 candidate SNPs for ovarian cancer. Int. J. Cancer 123 (2008) 380-388
42. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J. Natl. Cancer Inst. 90 (1998) 1774-1786
43. Risch N., and Merikangas K. The future of genetic studies of complex human diseases. Science 273 (1996) 1516-1517
44. Rodriguez G.C., Nagarsheth N.P., Lee K.L., Bentley R.C., Walmer D.K., Cline M., Whitaker R.S., Isner P., Berchuck A., Dodge R.K., and Hughes C.L. Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J. Natl. Cancer Inst. 94 (2002) 50-60
45. Rodriguez G.C., Walmer D.K., Cline M., Krigman H., Lessey B.A., Whitaker R.S., Dodge R., and Hughes C.L. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis?. J. Soc. Gynecol. Investig. 5 (1998) 271-276
46. Sachidanandam R., Weissman D., Schmidt S.C., Kakol J.M., Stein L.D., Marth G., Sherry S., Mullikin J.C., Mortimore B.J., Willey D.L., Hunt S.E., Cole C.G., Coggill P.C., Rice C.M., Ning Z., Rogers J., Bentley D.R., Kwok P.Y., Mardis E.R., Yeh R.T., Schultz B., Cook L., Davenport R., Dante M., Fulton L., Hillier L., Waterston R.H., McPherson J.D., Gilman B., Schaffner S., Van Etten W.J., Reich D., Higgins J., Daly M.J., Blumenstiel B., Baldwin J., Stange-Thomann N., Zody M.C., Linton L., Lander E.S., and Altshuler D. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409 (2001) 928-933
47. Schildkraut J.M., Calingaert B., Marchbanks P.A., Moorman P.G., and Rodriguez G.C. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J. Natl. Cancer Inst. 94 (2002) 32-38
48. Schildkraut J.M., Schwingl P.J., Bastos E., Evanoff A., and Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet. Gynecol. 88 (1996) 554-559
49. Sellers T.A., Huang Y., Cunningham J., Goode E.L., Sutphen R., Vierkant R.A., Kelemen L.E., Fredericksen Z.S., Liebow M., Pankratz V.S., Hartmann L.C., Myer J., Iversen Jr. E.S., Schildkraut J.M., and Phelan C. Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 397-404
50. Shattuck-Eidens D., Oliphant A., McClure M., McBride C., Gupte J., Rubano T., Pruss D., Tavtigian S.V., Teng D.H., Adey N., Staebell M., Gumpper K., Lundstrom R., Hulick M., Kelly M., Holmen J., Lingenfelter B., Manley S., Fujimura F., Luce M., Ward B., Cannon-Albright L., Steele L., Offit K., Thomas A., et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278 (1997) 1242-1250
51. Shen J., Ambrosone C.B., DiCioccio R.A., Odunsi K., Lele S.B., and Zhao H. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 29 (2008) 1963-1966
52. Song H., Koessler T., Ahmed S., Ramus S.J., Kjaer S.K., Dicioccio R.A., Wozniak E., Hogdall E., Whittemore A.S., McGuire V., Ponder B.A., Turnbull C., Hines S., Rahman N., Eeles R.A., Easton D.F., Gayther S.A., Dunning A.M., and Pharoah P.D. Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer. Cancer Res. 68 (2008) 8837-8842
53. Song H., Ramus S.J., Kjaer S.K., Hogdall E., Dicioccio R.A., Whittemore A.S., McGuire V., Hogdall C., Jacobs I.J., Easton D.F., Ponder B.A., Dunning A.M., Gayther S.A., and Pharoah P.D. Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. PLoS ONE 2 (2007) e268
54. Song H., Ramus S.J., Quaye L., DiCioccio R.A., Tyrer J., Lomas E., Shadforth D., Hogdall E., Hogdall C., McGuire V., Whittemore A.S., Easton D.F., Ponder B.A., Kjaer S.K., Pharoah P.D., and Gayther S.A. Common variants in mismatch repair genes and risk of invasive ovarian cancer. Carcinogenesis 27 (2006) 2235-2242
55. Song H., Ramus S.J., Shadforth D., Quaye L., Kjaer S.K., Dicioccio R.A., Dunning A.M., Hogdall E., Hogdall C., Whittemore A.S., McGuire V., Lesueur F., Easton D.F., Jacobs I.J., Ponder B.A., Gayther S.A., and Pharoah P.D. Common variants in RB1 gene and risk of invasive ovarian cancer. Cancer Res. 66 (2006) 10220-10226
56. Spillman M.A., Schildkraut J.M., Halabi S., Moorman P., Calingaert B., Bentley R.C., Marks J.R., Murphy S., and Berchuck A. Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. Gynecol. Oncol. 97 (2005) 543-549
57. Szabo C.I., and King M.C. Population genetics of BRCA1 and BRCA2. Am. J. Hum. Genet. 60 (1997) 1013-1020
58. The International HapMap Project. The International HapMap Project. Nature 426 (2003) 789-796
59. Thompson E., Dragovic R.L., Stephenson S.A., Eccles D.M., Campbell I.G., and Dobrovic A. A novel duplication polymorphism in the FANCA promoter and its association with breast and ovarian cancer. BMC Cancer 5 (2005) 43
60. Thorisson G.A., Smith A.V., Krishnan L., and Stein L.D. The International HapMap Project web site. Genome Res. 15 (2005) 1592-1593
61. Wacholder S., Chanock S., Garcia-Closas M., El Ghormli L., and Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J. Natl. Cancer Inst. 96 (2004) 434-442
62. Whittemore A.S., Harris R., and Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am. J. Epidemiol. 136 (1992) 1184-1203
63. Yan L., Na W., Shan K., Xiao-Wei M., Wei G., and Shu-Cheng C. p16(CDKN2) gene polymorphism: association with histologic subtypes of epithelial ovarian cancer in China. Int. J. Gynecol. Cancer 18 (2008) 30-35